cedalizumab

Cedalizumab (IA-103) is a humanized monoclonal antibody agonist targeting **4-1BB** (CD137), a co-stimulatory member of the tumor necrosis factor receptor (TNFR) superfamily. Developed by **Beijing Immune Ark Pharmaceutical Technology** (Immunoah), the agent is designed to bind specifically to 4-1BB expressed on activated T cells and natural killer (NK) cells, triggering downstream signaling pathways that enhance immune cell proliferation, survival, and anti-tumor effector functions. Cedalizumab aims to provide potent anti-tumor activity while maintaining a manageable safety profile, particularly seeking to avoid the dose-limiting hepatotoxicity associated with earlier generations of 4-1BB agonists. The drug is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, including melanoma and urothelial carcinoma. While Beijing Immune Ark retains overseas development rights, the rights for the Greater China region were transferred to a spinout entity.

Other names

cedalizumabIA-103IA103IA 103